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Background. The mechanical circulatory support (MCS) is an effective treatment in critically ill patients with end-stage heart
failure (ESHF) that, however, may cause a severe multiorgan failure syndrome (MOFS) in these subjects. The impact of altered
inflammatory response, associated to MOFS, on clinical evolution of MCS postimplantation patients has not been yet clarified.
Methods. Circulating cytokines, adhesionmolecules, and amarker ofmonocyte activation (neopterin) were determined in 53MCS-
treated patients, at preimplant and until 2 weeks. MOFS was evaluated by total sequential organ failure assessment score (tSOFA).
Results. During MCS treatment, 32 patients experienced moderate MOFS (tSOFA< 11; A group), while 21 patients experienced
severe MOFS (tSOFA≥ 11) with favorable (B group) or adverse (𝑛 = 13, C group) outcomes. At preimplant, higher values of
left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate (eGFR) were the only parameter independently
associated with A group. In C group, during the first postoperative week, high levels of interleukin-8 (IL-8) and tumor necrosis
factor (TNF)-𝛼, and an increase of neopterin and adhesionmolecules, precede tSOFAworsening and exitus. Conclusions.TheMCS
patients of C group show an excessive release to IL-8 and TNF-𝛼, and monocyte-endothelial activation after surgery, that might
contribute to the unfavourable evolution of severe MOFS.
1. Introduction
The mechanical circulatory support (MCS) device implan-
tation has emerged as an alternative treatment strategy in
critical ill patients with advanced heart failure (HF) [1].
The MCS devices are mechanical pumps that supplement or
replace the function of a damaged left ventricle in order to
maintain appropriate blood flow among patients with end-
stageHF (ESHF). In addition to supporting circulation,MCS,
in particular left ventricular assist devices, can lead to other
cardiac benefits, such as improved contractility, reduction
of hypertrophy, and reversal of chamber enlargement [2].
Left ventricular assist devices are mainly used as a bridge to
transplant, with the aim of increasing patient survival until
an appropriate organ becomes available [3].
Overall, in critically ill patients, the negative impact of
chronic comorbidity on survival is primarily influenced by
the degree of multiple organ failure syndrome (MOFS) or
the cumulative severity ofmultiple comorbidities [4]. Indeed,
despite advances in technology and subsequent improve-
ments in morbidity and mortality of patients undergoing
MCS placement, postimplantation MOFS, and infections
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remain the major causes of death in these patients [5, 6].
The MOFS seems to be influenced by the degree of the
immune-inflammatory response independently of the pres-
ence of infection. In MCS-treated patients, liver dysfunction
was shown to be associated to the progressive release of
inflammatory mediators, such as interleukin-6 (IL-6), IL-
8, and C-reactive protein (CRP) [7]. Moreover, platelets
and monocytes activation is associated with different MCS
devices suggesting a role of their interaction in the devel-
opment of haematic complications [8]. However, the impact
of inflammatory response on MOFS development after MCS
implant still needs to be elucidated.
The aim of this study was to investigate, in MCS-treated
patients, the early inflammatory signals associated to differ-
ent MOFS degrees and to their clinical evolution.
2. Materials and Methods
2.1. Population and Study Design. We included in the study
53 patients with ESHF, not amenable to recovery by pharma-
cological or conventional surgical therapy, who underwent
MCS, according to guideline indications for mechanical
support [9].
The hemodynamic parameters, cardiac index (CI), pul-
monary capillary wedge pressure (PCWP), and right atrial
pressure were measured by pulmonary artery Swan-Ganz
catheter. Left ventricular ejection fraction (LVEF) was quan-
tified by transesophageal echocardiography.
We calculated the total sequential organ failure assess-
ment score (tSOFA) according to Pa¨tila¨ et al. [10] as the high-
est SOFA value from preimplant to two weeks after surgery.
This score is a measure of MOFS development and risk of
mortality in the intensive care unit after cardiac surgery.
The SOFA is a six-organ (respiration, coagulation, liver,
neurological, cardiovascular, and renal) dysfunction/failure
score measuring multiple organ failure daily. Each organ is
graded from 0 (normal) to 4 (the most abnormal), providing
a daily score of 0 to 24 points.
In sedated patients, the neurological score was computed
retrospectively, when sedatives were stopped, alternatively,
after their temporary discontinuation. Renal function was
assessed by estimated glomerular filtration rate (eGFR) using
the abbreviated formula [11].
This study compliedwith the principles of theDeclaration
of Helsinki. The study protocol has been approved by the
Ethics Committee of Niguarda Ca` Granda Hospital (Milan,
Italy) and a signed informed consent has been obtained by all
participating patients.
Peripheral blood samples for biochemical assessment
were collected in fasting condition preimplant and after 4
hours 1 day, 3 days, 7 days, and 14 days fromMCS.
2.2. Biochemical Assessment. Plasma and serum samples
were obtained after blood centrifugation at 4000 rpm for 10
minutes.
Plasma interleukin-6 (IL-6), IL-8, IL-10, tumor necro-
sis factor (TNF)-𝛼, IL-1 receptor antagonist (IL-1ra), solu-
ble platelet selectin (sP-selectin), and soluble intercellular
adhesion molecule type 1 (sICAM-1) were measured using
specific enzyme-linked immunoassays kits (R&D Systems,
Minneapolis, MN-USA for IL-6, IL-8, IL-10, IL-1ra, sP-
selectin, and sICAM-1; Cayman, Ann Arbor, MI-USA for
TNF-𝛼) that allow an easy and accurate quantification based
on antibody reaction.
Serum CRP levels were evaluated by high-sensitive
immune-turbinometric assay (Roche Diagnostic GmbH)
which use an anti-CRPmonoclonal antibody immobilized on
latex particles.
Urinary neopterin levels were measured by an isocratic
HPLC method, previously reported [12], and normalized
by urine creatinine concentrations. Briefly, urine samples
were adequately diluted with chromatographic mobile phase
(15mM of K
2
HPO
4
, pH 3.0). Neopterin and creatinine
levels were assessed using a Kontron instrument (pump
422-S, autosampler 465) coupled to a fluorometric detector
(JASCO FP-1520, 𝜆ex = 355 nm and at 𝜆em = 450 nm) for
neopterin detection and to a UV-VIS detector (BIO-RAD
1706, 𝜆 = 240 nm) for creatinine determination. Neopterin
and creatinine separations were performed at 50∘C on a 5 𝜇m
DiscoveryC18 analytical column (250× 4.6mm I.D., Supelco,
Sigma-Aldrich) at flow rate of 0.9mL/min.
2.3. Statistical Analysis. Data are presented as median and
interquartile range (25th–75th) or frequency. Retrospectively,
patients were categorized into three groups: A, B, and C,
according to severity grade of MOFS and 3-month outcome.
Comparison among groups was conducted by a one-way
analysis of variance, or Kruskall-Wallis in case of skewed
variables, with Bonferroni post hoc test for continuous
variables and by a chi-square test for categorical variables.
Multivariable ordinal logistic regression models were con-
structed to examine the effect of biochemical and clinical
parameters with group of MOFS severity as the dependent
variable. Results are presented as odds ratio (OR) and their
95% confidence interval (CI). Differences across time within
patient groups were assessed by nonparametric Friedman
test.
A two-tailed 𝑃 value <0.05 was considered statistically
significant. All statistical tests were done with SPSS version
17.0 software (SPSS, Inc., Chicago, IL, USA).
3. Results
Clinical data of candidates to MCS implantation and opera-
tive characteristics are described inTable 1. Patient age ranged
from 22 to 72 years (median 54 (48–61)). Thirty patients
had idiopathic dilated cardiomyopathy, twenty-two ischemic
cardiomyopathies, and one acute myocarditis. At preimplant,
37 patients were receiving inotropes. Median tSOFA score
was 5 (3–7).
In 49 patients intrathoracic left ventricular assist devices
were implanted (48 continuous flow pumps (8 DeBakey,
6 Incor, 32 HeartMateII, 2 HeartWare), and 1 pulsatile-
flow pump (Novacor)) while in 4 patients an extracorporeal
continuous-flow, centrifugal-type rotary pump (Levitronix
LLC) was implanted.
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Table 1: Clinical characteristics of patients and perioperative data.
All cases max tSOFA score < 11 max tSOFA score ≥ 11
𝑃
(𝑛 = 53) (Group A = 32) Outcome + (group B = 8) Outcome − (group C = 13)
Age, years 54 (48–61) 52 (45–58) 53 (49–62) 57 (52–66) 0.052
Male gender, 𝑛 (%) 49 (93) 31 (97) 7 (88) 11 (85) 0.313
INTERMACS profile, 𝑛 (%) 0.610
1 15 (28) 8 (25) 2 (25) 5 (38)
2 15 (28) 10 (31) 2 (25) 3 (23)
3 22 (42) 14 (44) 4 (50) 4 (31)
4 1 (2) — — 1 (8)
Etiology, 𝑛 (%): 0.318
DCM 30 (57) 20 (63) 5 (63) 5 (39)
ICM 22 (41) 12 (37) 3 (37) 7 (53)
Myocarditis 1 (2) — — 1 (8)
MAP, mmHg 75 (70–85) 78 (72–85) 75 (69–83) 73 (68–83) 0.499
LVEF, % 21 (18–26) 23 (18–26) 26 (19–28) 20 (16–21) 0.045
LVEDV, mL 260 (190–312) 260 (190–330) 239 (174–326) 237 (161–292) 0.466
RAP, mmHg 6 (4–10) 5 (3–8) 8 (4–15) 9 (4–16) 0.163
PCWP, mmHg 24 (18–30) 24 (15–30) 23 (10–33) 24 (19–31) 0.865
CI, L/min/m2 1.69 (1.36–2.00) 1.70 (1.51–2.08) 1.32 (1.07–1.47)∗ 1.69 (1.45–1.83) 0.023
Treatments, 𝑛 (%)
ACEi + ATII 34 (67) 21 (68) 5 (63) 8 (67) 0.961
Beta-blocker 31 (61) 20 (65) 6 (75) 5 (42) 0.259
Statins 13 (27) 9 (30) 2 (25) 2 (18) 0.745
Diuretics 39 (77) 25 (81) 7 (88) 7 (58) 0.219
Inotropic 37 (71) 23 (72) 5 (63) 9 (75) 0.824
Inotropic equivalents, 𝑛 5 (0–10) 4 (0–9) 4 (0–8) 9 (1–13) 0.335
IABP, 𝑛 (%) 22 (43) 13 (42) 2 (25) 7 (58) 0.329
WBC, 109/L 8.4 (7.1–11.4) 8.8 (7.2–11.9) 8.5 (5.6–17.2) 8.4 (6.5–9.4) 0.580
INR 1.2 (1.1–1.4) 1.2 (1.0–1.5) 1.2 (1.1-1.2) 1.2 (1.1–1.4) 0.407
Lactate, mg/dL 1.0 (0.8–1.8) 1.2 (0.8–1.7) 1.0 (0.7–1.8) 1.0 (0.8–2.8) 0.814
eGFR, mL/min/1.73m2 80 (58–100) 86 (74–116) 57 (50–76)∗ 59 (42–76)∗ 0.001
t-Bil, mg/dL 1.04 (0.63–1.86) 0.98 (0.61–1.89) 1.28 (0.89–2.37) 0.84 (0.57–1.91) 0.482
tSOFA score, 𝑛 5 (3–7) 4 (2–6) 5 (3–7) 6 (5–10) 0.051
Perioperative data
Surgery time, min 310 (255–375) 308 (270–368) 340 (308–383) 275 (213–390) 0.312
CPB time, min 83 (68–102) 81 (65–104) 88 (68–122) 84 (72–96) 0.828
Data are expressed as median and interquartile range (25th–75th) or number (percentage).
ACEi: angiotensin converting enzyme inhibitor; t-Bil: total Bilirubin; BUN: blood urea nitrogen; CI: cardiac index; CPB: cardiopulmonary bypass; DCM:
dilated cardiomyopathy; ECMO: extracorporeal membrane oxygenation; eGFR: estimated glomerular filtrate rate; IABP: intra-aortic balloon pump; ICM:
ischemic cardiomyopathy; INR: international normalized ratio; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support; LVEF: left
ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; MAP: mean arterial pressure; PCWP: pulmonary capillary wedge pressure; RAP:
right atrial pressure; tSOFA: total sequential organ failure assessment; WBC: white blood cell count; +: positive; −: negative.
∗
𝑃 < 0.05 versus group A patients by Bonferroni post-hoc test.
During ICU stay, 21 patients (40%) experienced post-
operative maximal tSOFA score ≥ 11, taken into account as
severe MOFS associated with elevated mortality rates [13].
Among these patients, 13 (62% of this group) died because
of MOFS as primary or secondary cause of death, in a
median of 13 (11–25) days. In particular, 3 patients suffered
of hepatic injury, 3 suffered of intestinal ischemia, 2 showed
a nonresponsive vasoplegia, 3 had respiratory failure, 1 was
affected by major esophagus bleeding, and 1 was affected
by disseminated intravascular coagulation. The other 32
experienced moderate MOFS with postoperative maximal
tSOFA score < 11; they were all alive at 3 months after
intervention.
Retrospectively, MCS-candidates were divided in 3
groups according to severity grade of post-operative MOFS
and 3-month outcome. Group A: consisting of 32 patients
with maximal post-operative tSOFA score < 11 and without
adverse events; group B: 8 patients with favorable outcome at
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Table 2: Preimplant inflammatory characteristics.
All cases max tSOFA score < 11 max tSOFA score ≥ 11
𝑃
(𝑛 = 53) (Group A = 32) Outcome + (group B = 8) Outcome − (group C = 13)
TNF-𝛼, pg/mL 9.3 (5.2–12.1) 6.9 (5.0–10.4) 10.3 (2.6–16.3) 9.7 (9.4–14.0) 0.081
IL-6, pg/mL 9.8 (3.6–27.4) 6.8 (3.0–24.1) 17.8 (6.1–118.7) 25.6 (9.6–63.4) 0.067
IL-8, pg/mL 7.6 (5.2–13.6) 7.7 (5.5–11.3) 5.1 (3.7–14.4) 13.1 (5.3–24.2) 0.294
C-reactive protein, mg/dL 1.5 (0.5–3.9) 1.2 (0.3–3.1) 2.2 (0.8–13.1) 2.2 (1.1–8.4) 0.108
IL-10, pg/mL 1.8 (0–7.5) 1.8 (0–8.0) 1.7 (0–6.2) 2.2 (0–14.4) 0.824
IL-1ra, pg/mL 518 (311–1276) 491 (295–840) 785 (268–1955) 828 (468–1898) 0.137
sICAM-1, pg/mL 300 (224–433) 291 (226–397) 332 (220–676) 323 (210–528) 0.739
sP-selectin/PLT, pg/106 288 (164–505) 221 (173–476) 410 (217–622) 337 (122–537) 0.742
Neo/Cr ratio, 𝜇mol/mol 290 (199–563) 279 (181–457) 317 (128–549) 337 (240–698) 0.422
Data are expressed as median and interquartile range (25th–75th).
IL: interleukin;Neo/Cr: neopterin levels normalized by urine creatinine levels; sICAM-1: soluble formof intercellular adhesionmolecule type 1; sP-selectin/PLT:
soluble platelet selectin normalized by platelet count; TNF: tumor necrosis factor; +: positive; −: negative.
3 months but with maximal postoperative tSOFA score ≥ 11;
and group C involving the other 13 patients with and tSOFA
score ≥ 11 and adverse lethal event. Detailed pre-implant
characteristics and peri-operative data of these 3 groups are
described in Table 1. Age, aetiology and Interagency Reg-
istry for Mechanically Assisted Circulatory Support (INTER-
MACS) profiles were comparable among groups as well as
the medical therapies. The LVEF and CI values are the only
echocardiographic and hemodynamic parameters that differ
among A, B, and C groups.The tSOFA score and eGFR values
were different among groups, in particular eGFR levels of B
and C groups were lower than those of A group. Variables
related to surgery as well as type of MCS devices used (data
not shown) were comparable among groups.
3.1. Preimplant Inflammatory Status. At preimplant, the
levels of proinflammatory (TNF-𝛼, IL-6, IL-8) and anti-
inflammatory (IL-10 and IL-1ra) cytokines, and adhesion
molecules (sICAM-1 and sP-selectin), Neopterin/Creatinine
ratios and CRP were similar among groups (Table 2).
3.2. Preimplant Clinical Variables Associated with Moderate
MOFS. All the variables of Tables 1 and 2 that reached a
P value <0.05 were entered into the multivariable ordinal
logistic regression analysis. The only variables independently
associated to group Awere LVEF and eGFR levels (LVEF: OR
0.847, 95% CI 0.734–0.977, 𝑃 = 0.024; eGFR: OR 0.936, 95%
CI 0.898–0.975, 𝑃 = 0.001).
3.3. Postoperative Hemodynamic, tSOFA Score, and CRP Pro-
files. Postoperative recovery and hemodynamic parameters
were similar among groups and were maintained during
MCS.
At 1–3 postoperative days (Figure 1(a)), t-SOFA score was
significantly higher in patients of B and C groups compared
to A group, while at 7 and 14 days, this parameter remained
higher only in C group compared to the others.
Serum levels of CRP were similar among group till 3
days after intervention (Figure 1(b)) but they significantly
increased in B group compared to A group at 7 days
postimplant. At 14 days, only patients of C group showed
higher CRP levels with respect to A groupwhile no difference
was instead observed between B and C groups.
3.4. Postoperative Profiles of Proinflammatory Cytokines and
Neopterin. At 1 postoperative day (Figure 2(a)), TNF-𝛼 levels
significantly increased in patients of C group with respect to
A group, while after 3 and 7 days the TNF-𝛼 concentrations
of C group were higher compared to both A and B groups.
IL-6 levels (Figure 2(b)) differed among groups at 7 days
but also at 14 days with B and C groups having higher IL-6
concentrations than those of A group.
At 1 and 3 postoperative days, IL-8 levels (Figure 2(c))
were significantly increased in C group than in A group while
at 7 and 14 days, the IL-8 concentrations of C group were also
significantly higher compared with those of B group.
In regard to neopterin, an established marker of mono-
cyte activation, we observed an increase of its concentration
in patients of C groups with respect to A group at 1, 3, and 7
days (Figure 2(d)).
No significant differences of TNF-𝛼, IL-8, and neopterin
levels at each postoperative point were observed between A
and B groups.
3.5. Postoperative Profiles of Anti-Inflammatory Cytokines.
The IL-10 levels (Figure 3(a)) were significantly different in
C group than in A group at 7 and 14 days while the IL-1ra
concentrations (Figure 3(b)) were different between C and A
groups of patients at 1, 3, 7, and 14 days after intervention but
also with B group at 14 days.
3.6. Postoperative Profiles of Adhesion Molecules. sP-selectin
o and sICAM-1 levels (Figures 4(a) and 4(b)) were increased
in patients of C group than in those of A group at 7 days post
device implant.
No significant differences of sP-selectin and sICAM-1
levels were instead observed between A- and B-groups.
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Figure 1: (a) Time course of the t-SOFA score and (b) CRP levels in patients that experienced postoperative maximal tSOFA score < 11
(group A: empty box-plots), and patients with postoperative maximal tSOFA score ≥ 11, with positive (group B: light gray box-plots) or
negative (group C: dark gray box-plots) 3-month outcome. The tSOFA score ≥ 11 is pointed out by a dashed line. 𝑃 values are for differences
among groups at each time-point by Kruskall-Wallis text. ∗𝑃 < 0.05 versus groupA byMann-Whitney text corrected by Bonferroni. ∘𝑃 < 0.05
versus group B by Mann-Whitney text corrected by Bonferroni.
3.7. Postoperative IL-8 and TNF-𝛼 Exposure according to
Patient Groups. The grade of patient exposure to TNF-𝛼
and IL-8 during the first postoperative week was measured
calculating the area under the curve of respective levels of
cytokines from 4 hours at 1 week (equal to 164 hours) after
intervention (AUC
164 hrs) by trapezoidal rule. The AUC164 hrs
of TNF-𝛼 and IL-8 were differently distributed among patient
groups (Figure 5). In particular, the TNF-𝛼 AUC
164 hrs of C
group was higher with respect to A group, while the IL-8
AUC
164 hrs of C group was higher than those of A and B
groups of patients (Figures 5(a) and 5(b)).
The AUC
164 hrs of TNF-𝛼 and IL-8 of B group were
comparable to those of A group.
4. Discussion
This study investigated the clinical characteristics and inflam-
matory mechanisms associated to evolution of severe mul-
tiorgan dysfunction in patients affected by ESHF after MCS
device implantation. The study shows that ESHF patients,
with preoperative reduced LVEF and eGFR values, are more
susceptible to develop a severe MOFS and thus an unfa-
vorable outcome after MCS intervention. During the first
postoperative week, the grade of inflammatory response,
particularly linked to early IL-8 and TNF-𝛼 exposure, is
associated to the clinical evolution of patients with severe
MOFS.
The application of MCS has become an effective ther-
apeutic option for treatment of deteriorating phase of HF.
However MOFS remains a frequent early complication in
MCS-treated patients, and an adequate knowledge of the
mechanisms involved in its onset and deterioration are still
lacking. Several studies reported that, after cardiac surgery,
the grade of MOFS severity developed in the first days of
ICU stay and is associated to the clinical outcome. High
tSOFA scores are proposed as useful outcome predictors [13];
independently of the starting value, a tSOFA score ranging
from 8 to 11 during the first 48 hours in the ICU, is associated
to a mortality rate of 60 to 90%. In the present study, we used
an increase in tSOFA scores ≥ 11 during the first weeks in ICU
as threshold value to distinguish MCS patients developing
a severe MOFS from those that experienced a moderate
multiorgan damage (tSOFA score < 11). This threshold score
has been able to discriminate also in our study patients at risk
to unfavorable outcome. In fact, the mortality rate of subjects
with tSOFA score ≥ 11 was 62%.
tSOFA value between patients of B and C groups was
comparably high until the third day postintervention but
decreased in B group at 7 and 14 days compared to C group,
suggesting that this period may be crucial for the clinical
evolution of these critical patients.
One day postintervention, the levels of cytokines, TNF-𝛼
and IL-8, and the urinary concentrations of neopterin signif-
icantly increased in C group compared to A and B groups.
Moreover, during the first postoperative week, C group of
patients showed a greater exposure to TNF-𝛼 and IL-8 with
respect to the other 2 groups. TNF-𝛼 is known to be involved
in systemic inflammatory response syndrome (SIRS), which
usually precedes MOFS in several ill patients [14, 15], while
IL-8 is a specific monocyte attracting chemokines that
modulates monocyte activation, an important condition in
organ damage and haemostatic complications [16]. These
data suggest that, immediately after MCS intervention, the
extent of inflammatory response relatedmainly toTNF-𝛼 and
IL-8 signals could influence the development and degree of
MOFS severity, contributing to subsequent clinical evolution
of ESHF patients.
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Figure 2: (a) Time course of plasma TNF-𝛼, (b) IL-6, (c) IL-8 levels, and (d) urine neopterin/creatinine ratio in patients that experienced
postoperativemaximal tSOFA score < 11 (group A: empty box-plots), and patients with postoperativemaximal tSOFA score ≥ 11, with positive
(group B: light gray box-plots) or negative (group C: dark gray box-plots) 3-month outcome. 𝑃 values are for differences among groups at
each time-point by Kruskall-Wallis text. ∗𝑃 < 0.05 versus group A by Mann-Whitney text corrected by Bonferroni. ∘𝑃 < 0.05 versus group B
by Mann-Whitney text corrected by Bonferroni.
On the contrary, CRP levels, the main inflammatory
variable routinely used in the setting of MCS-therapy, were
not able to early discriminate patients with unfavourable
outcome, suggesting that CRP profile does not reflects the
inflammatory pathways involved in the adverse evolution of
severe MOFS.
During the early phase of MCS, the exacerbate release
of anti-inflammatory cytokines (IL-10 and IL-1ra) in addi-
tion to a massive proinflammatory reaction, could pro-
duce an unbalance of inflammatory response which might
contributes to the onset of severe MOFS by causing
anergy and immunosuppression [17], a condition known as
immunoparalysis in patients with severe sepsis [18].
One postoperative week, patients with unfavorable evo-
lution of severe MOFS showed also elevated sP-selectin
and adhesion molecule sICAM while the neopterin levels
of these patients already increased 1 day after surgery. sP-
selectin is a marker of platelet and endothelial alteration
and a direct inducer of procoagulant activity associated
with thrombotic disease [19, 20]. sICAM is responsible for
neutrophil and leukocyte attachment to the endothelium [19]
while neopterin is a marker of macrophage/monocyte and
immune system activation. The activation of monocyte and
the injury of endothelium are factors that might contribute,
in the microcirculation, to the formation of microthrombi
and intravascular coagulation associated to development and
worsening of multiorgan failure [7].
In previous studies, involving MCS-treated patients with
left ventricular and biventricular supports, several preimplant
clinical characteristics such as cardiogenic shock, advanced
age, severe right heart failure, or increased bilirubine, were
found to be predictors of adverse outcomes [21, 22]. In
Mediators of Inflammation 7
700
600
500
400
300
200
100
0P
la
sm
a I
L-
10
 le
ve
ls 
(p
g/
m
L)
Time
13832 13832 13832 13832 13832 5832
14 days7 days3 days1 day4 hoursPreimplant
N =
P = 0.004
P = 0.039
∗
∗
(a)
300000
250000
200000
150000
100000
50000
0
Pl
as
m
a I
L-
1r
a l
ev
els
 (p
g/
m
L)
P = 0.015 P = 0.018
P = 0.004P = 0.020
∗ ∗
∗
Time
13832 13832 13832 13832 13832 5832
14 days7 days3 days1 day4 hours
N =
Preimplant
∗∘
(b)
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our series, patients characterized by lower LVEF values and
altered renal function before device implantation, developed
serious MOFS with unfavourable evolution after MCS inter-
vention. On the contrary, preimplant inflammatory media-
tors did not differ among groups, indicating that this mech-
anism is activated during or immediately after surgery. The
intensity and length of postimplant inflammatory response
seems to be an important trigger that influences the clinical
outcome of these patients.
Several studies have recently highlighted the emergent
role of specialized regulatory cell subtypes belonging to
myeloid-derived suppressor, monocyte phenotypes, and T
and B lymphocytes in the proresolution of inflammatory
pathways in critically ill patients [23, 24]. The evaluation of
these subtypes of inflammatory cells in subjects’ candidates
to MCS therapy could contribute to identify specific linkages
between cellular inflammatory status and unbalanced inflam-
matory response associated to unfavorable outcome.
5. Conclusions
A specific inflammatory sequence, involving inflammatory
signals dependent from TNF-𝛼 and IL-8, monocyte, and
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Figure 5: (a) The area under the curve of TNF-𝛼 and (b) IL-8 levels from 4 hours at 1 week after intervention (AUC
164 hrs) in patients that
experienced postoperative maximal tSOFA score < 11 (group A: empty box-plots), and patients with postoperative maximal tSOFA score ≥
11, with positive (group B: light gray box-plots) or negative (group C: dark gray box-plots) 3-month outcome. 𝑃 values are for differences
among groups by Kruskall-Wallis text. ∗𝑃 < 0.05 versus group A by Mann-Whitney text corrected by Bonferroni. ∘𝑃 < 0.05 versus group B
by Mann-Whitney text corrected by Bonferroni.
endothelial activation, contributes to the unfavourable evo-
lution of severe MOFS developed during the first weeks
after MCS therapy. Patients, characterized by preimplant low
ejection fraction and renal dysfunction, are more susceptible
to develop an unbalanced inflammatory response during
MCS therapy associated to a severe MOFS with negative
outcome. High TNF-𝛼, IL-8, and neopterin concentrations
may be considered as early markers of MOFS occurrence and
unfavourable outcome in end stage HF patients. The correct
timing to MCS implant is crucial to prevent the excessive
clinical deterioration after MCS implantation triggered by
an aberrant postoperative inflammatory response, which
adversely affects the clinical outcome of MCS therapy.
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